Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 1 results out of 1
Data Insights
Mivelsiran sodium by Alnylam Pharmaceuticals for Unspecified Central Nervous System Disorders: Likelihood of Approval
Mivelsiran sodium is under clinical development by Alnylam Pharmaceuticals and currently in Phase II for Unspecified Central Nervous System Disorders....